(RTTNews) - U.S. biomarker diagnostics company Quanterix Corp. (QTRX) announced on Monday that it has appointed physician executive Yuri Fesko as Chief Medical Officer. Fesko will provide medical and clinical leadership across the company, as it prepares for the broader launch of its Lucent AD Complete Alzheimer's test and advances regulatory filings for its HD-X instrument. Fesko had previously served as Chief Medical Officer at Quest Diagnostics, overseeing medical affairs, clinical development and public health. On the Nasdaq, shares of Quanterix are currently losing 0.78 percent, changing hands at $2.5400 (RTTNews) - U.S. biomarker diagnostics company Quanterix Corp.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。